It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies. Since many of these targets are not enzymes or surface receptors with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.
Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, ß-catenin and Myc.
Presentation of Target
Target Examples
Therapeutic Modality
Effector Function
The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.
Stakeholder analysis based on profiles of 45 companies active in the field
Analysis of partnering deals and financing rounds
Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, ß-catenin and Myc.
Presentation of Target
- On cell surface as peptide-MHC class I complex
- Intracellular;
- Intranuclear
- Protein-protein interaction (PPI)
Target Examples
- Neoantigens
- Gp100; NY-ESO-1; MAGE-A, PRAME; WT1; MART-1
- Beta-catenin; Myc; Ras
Therapeutic Modality
- TCR fusion protein
- TCR-like antibody
- Cell penetrating peptide, miniprotein or antibody incl. shuttle
Effector Function
- Fc-enhanced
- Bispecific (T-cell recruiting)
- Drug Conjugate
- Inhibition
This report `Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends` brings you up-to-date regarding key technologies:
- For identification and validation of intracellular targets,
- For generation of T-cell receptors (TCR) and TCR fusion proteins,
- For discovery of TCR-like antibodies, and
- For construction of cell-penetrating peptides, proteins and antibodies.
The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.
What will you find in the report?
Description and comparison of technologies for:
- Discovery and validation of intracellular targets;
- Discovery and optimization of T-Cell Receptors (TCRs);
- Generation of TCR-like or TCR-mimic antibodies;
- Generation of TCR fusion proteins
- Generation of cell-penetrating peptides, proteins and antibodies.
Presentation and discussion of profiles of selected product candidates:
- TCRL antibodies and TCR fusion proteins; and
- Cell-penetrating peptides, miniproteins and single domain and Ig antibodies
Stakeholder analysis based on profiles of 45 companies active in the field
Analysis of partnering deals and financing rounds
Table of Contents
1 Executive Summary2 Introduction & Overview3 Background
4 Technology Profiles
5 Pipeline Analysis and Product Profiles
6 Stakeholder Analysis & Company Profiles
7 Deals & Financing
Samples
LOADING...
Companies Mentioned
- AbbVie
- AbeXXa
- Adicet Bio
- Affimed Therapeutics
- Agenus
- Aileron Therapeutics
- Amgen
- Astellas Pharma
- AstraZeneca
- Atreca
- BioNTech
- Boehringer Ingelheim
- Complix
- Elasmogen
- Eli Lilly
- Eureka Therapeutics
- Feldan Therapeutics
- Fog Pharmaceuticals
- Gadeta
- Gilead Sciences (Kite Pharma)
- GlaxoSmith-Kline
- Immatics Biotechnologies
- Immunocore
- Innovative Targeting Solutions (ITS)
- Janssen Biotech
- Juno Therapeutics
- MD Anderson Cancer Center
- Medigene
- Merck
- Morphosys
- NantCell (Altor Bioscience)
- Nextera
- Novartis
- Orum Pharmaceuticals
- Patrys
- Pure MHC
- Receptor Logic (now Pure MHC)
- Regeneron Pharmaceuticals
- Roche
- Singh Biotechnology
- Sorrento Therapeutics & LA Cell
- Timmune Biotech
- Xencor
- ZIOPHARM Oncology
- Zymeworks